Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 1.00 |
| ▸ | DHODH | Q02127 | 18/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51144 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29394998 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL51143 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914885 | 0.89 | ALDH1A1 (0.80) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914888 | 0.89 | ALDH1A1 (0.80) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL28057335 | 0.84 | MEN1 (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914906 | 0.82 | MEN1 (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914905 | 0.82 | MEN1 (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914890 | 0.79 | DHODH (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914891 | 0.79 | DHODH (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | UNIV INDIANA RES & TECH CORP (US) | 2026-01-29 | — | — | US | claimed |
| US-20260014140-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2025-09-25 | — | — | US | claimed |
| EP-4531856-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK-Abelló A/S (DK) | 2025-04-09 | — | — | EP | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-20220054648-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | IMMUNOMEDICS, INC. | 2022-02-24 | — | — | US | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-9820987-B2 | Modulator compounds of drug resistance in epithelial tumor cells | BIONSIL S.R.L. IN LIQUIDAZIONE (IT) | 2017-11-21 | — | — | US | claimed |
| WO-2017042706-A1 | PHARMACEUTICAL KIT AND USE OF ERYTHROPOIETIN AND BRUTON'S KINASE INHIBITOR | UNIWERSYTET MEDYCZNY W BIAŁYMSTOKU (PL) | 2017-03-16 | — | — | WO | claimed |
| US-20160201111-A1 | Method and Apparatus for Measuring Protein Post-Translational Modification | UNITED STATES GOVERNMENT | 2016-07-14 | — | — | US | claimed |
| US-20150111953-A1 | Modulator Compounds of Drug Resistance in Epithelial Tumor Cells | BIONSIL S.R.L. IN LIQUIDAZIONE (IT) | 2015-04-23 | — | — | US | claimed |
| US-8129356-B2 | Bmx mediated signal transduction in irradiated vascular endothelium | VANDERBILT UNIVERSITY (US) | 2012-03-06 | — | — | US | claimed |
| US-20090136487-A1 | BMX MEDIATED SIGNAL TRANSDUCTION IN IRRADIATED VASCULAR ENDOTHELIUM | VANDERBILT UNIVERSITY | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | MYLK3, MYL12A, MYLK2 | MEN1 4427/4885ALDH1A1 4727/4885KMT2A 3198/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | MEN1 1475/4885ALDH1A1 586/4885KMT2A 445/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MEN1 1822/4885ALDH1A1 1814/4885KMT2A 1324/4885 |
| US-20260014140-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | CD74, CD2, CD274 | MEN1 1668/4885ALDH1A1 1361/4885KMT2A 4014/4885 |
| US-20150111953-A1 | Modulator Compounds of Drug Resistance in Epithelial Tumor Cells | BTK, PRKDC, PCLAF | MEN1 3314/4885ALDH1A1 4313/4885KMT2A 1708/4885 |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | BTK, SYK, ABL1 | MEN1 3540/4885ALDH1A1 4690/4885KMT2A 1325/4885 |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | MSR1, TNFRSF9, TNFSF10 | MEN1 1176/4885ALDH1A1 4392/4885KMT2A 3061/4885 |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | CXCR6, BCL6, CXCR4 | MEN1 1767/4885ALDH1A1 2271/4885KMT2A 1586/4885 |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | PARP2, DOCK2, DYNLL2 | MEN1 4148/4885ALDH1A1 3269/4885KMT2A 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.